Enanta Pharma Q4 net loss $24.6M; FY net loss $79M; terminates HBV asset, plans COVID protease inhibitor

ENANTA PHARMACEUTICALS INC

2021-FY EPS reported -$3.92 revenue$97,074,000

Q4 revenue $23.6M (flat YoY); net loss $24.6M ($1.22 loss per diluted share) vs $29.3M loss a year ago.
FY revenue $97.1M (down 21% from $122.5M); net loss $79M ($3.92 loss per diluted share) vs $36.2M loss.
Terminated EDP-721 (HBV RNA destabilizer) due to adverse safety signals; positive Phase 1b data for EDP-514 HBV core inhibitor.
Plans to advance EDP-235 oral protease inhibitor for COVID-19 into Phase 1 in early 2022.
Discontinued internal NASH FXR agonist development; will pursue out-licensing; FY2022 guidance: R&D $150-170M, G&A $35-41M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.